ABSTRACT: Simvastatin, an inexpensive lipid-lowering drug widely used to prevent cardiovascular disorders, is known to increase osteoblastic activity, inhibit osteoclastic activity, and stimulate osteoblastic production of bone morphogenetic protein 2. Furthermore, local simvastatin application increased bone formation in animal models of fracture or bone defects. We investigated the effect of locally applied simvastatin in a rat model of spinal fusion. We performed posterolateral lumbar fusion surgery with iliac crest autograft in 36 rats divided into group I (n ¼ 17; implanted with a gelatin scaffold) and group II (n ¼ 19; implanted with a gelatin scaffold infused with 0.5 mg simvastatin). The rats were euthanized at 6 or 12 weeks postoperatively, and the spines were explanted and assessed. The fusion rates in group II (16.7%: 6 weeks, 30%: 12 weeks) were considerably higher than those in groups I (0%: 6 weeks, 0%: 12 weeks). The 6-and 12-week radiographic scores were significantly higher in group II than in group I. High-resolution micro-computerized tomography revealed that the tissue and bone volumes of the callus tended to be higher in group II than in group I. Histologic analysis of the spines explanted after 12 weeks demonstrated new bone formation between the transverse processes in group II, but thicker and wider individual trabeculae with fibrotic tissue and muscle fiber between the transverse processes in group I. Locally applied simvastatin was efficacious in accelerating bone formation in our rat model of spinal fusion, supporting its potential clinical application as a promoter of bone morphogenesis in spinal fusion. ß 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:1942Res 35: -1948Res 35: , 2017.
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor b superfamily, with a potent effect in stimulating bone formation. With respect to spinal fusion, the osteoinductive effects of recombinant human BMPs (rhBMPs) have been demonstrated in both animal models and clinical trials, leading to the approval of rhBMP-2 for clinical use. [1] [2] [3] [4] [5] However, the results of the clinical trials show that large doses of rhBMPs are required to induce adequate bone fusion, which is associated with high costs. 6 Therefore, it is desirable to develop therapeutic approaches using alternative pharmacological stimulators of bone formation.
Simvastatin, a type of statin, is an inexpensive lipid-lowering drug widely used to prevent cardiovascular disorders. Statins interfere with the synthesis of hepatic cholesterol by inhibiting 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in the production of cholesterol via the mevalonate pathway 7 ; thus, statins can lower serum cholesterol levels 8 and significantly reduce mortality associated with coronary heart disease. 9 In addition to reducing blood cholesterol levels, statins also have a pleiotropic effect of inhibition over mevalonate metabolism. Specifically, the mevalonate pathway results in the production of isoprenoids, which are essential for several cellular functions. Therefore, statin-induced inhibition of HMG-CoA reductase is associated with multiple changes, such as antioxidant, anti-inflammatory, and anti-carcinogenic effects noted in animal models, as well as stabilization of atherosclerotic plaques, anticoagulant effects, inhibition of graft rejection, and anabolic action noted in bone tissues. [10] [11] [12] Moreover, statins induce the expression of BMP-2 and vascular endothelial growth factors, which represent bone anabolic factors [12] [13] [14] and inhibit osteoclastogenesis. 15 In view of these findings, it has been suggested that statins may have beneficial effects in the spinal bone fusion. In the present study, we aimed to investigate the effect of locally applied simvastatin on bone formation in a rat model of spinal fusion, and to examine the feasibility of locally applied simvastatin in clinical settings involving spinal fusion.
MATERIALS AND METHODS

Preparation of Matrices
A biodegradable gelatin hydrogel scaffolding for cellular attachment (MedGEL, Kyoto, Japan), was cut with a scalpel into 5 Â 10-mm strips and prepared for implantation by being treated with 50 ml phosphate-buffered saline solution (PBS, pH 7.5) containing 0.5 mg simvastatin (Wako Junyaku Inc., Osaka, Japan) or with 50 ml PBS without simvastatin (negative control), and left overnight at 4˚C in an Eppendorf tube prior to implantation.
Animals
The study was conducted after approval was obtained from the Animal Research Committee of Oita University. Thirty-six male Sprague-Dawley rats (16-18 weeks old; CLEA Japan, Inc., Tokyo, Japan) were divided into two groups according to whether the scaffolding gel was infused with simvastatin. Specifically, the animals in group I (n ¼ 17) were implanted with the gelatin scaffold only, whereas the animals in group II (n ¼ 19) were implanted with the gelatin scaffold infused with 0.5 mg simvastatin.
Surgical Technique for Developing a Rat Model of L4-L5 Posterolateral Spinal Fusion A posterior midline incision was made on the skin, followed by two separate paramedian incisions in the lumbar fascia, at 3 mm from the midline, to expose the transverse processes. Next, the transverse processes of L4 and L5 were decorticated using a low-speed burr, and the gelatin scaffold (with or without simvastatin) was implanted on the fusion bed combined with the harvested iliac crest autograft. The fascial and skin incisions were closed with a 3-0 absorbable suture. Immediately following surgery and on subsequent days, the rodents received analgesics (buprenorphine subcutaneously and paracetamol). The rodents were housed in separate cages and fed food and water ad libitum, and their conditions were monitored on a daily basis. The rats were humanly euthanized at 6 or 12 weeks after surgery. The explanted spines were assessed via manual palpation, radiography, highresolution micro-computerized tomography (micro-CT), and histological analysis.
Manual Assessment of Fusion
Six or twelve weeks after surgery, explanted spines were manually tested for intersegmental motion by three blinded independent observers. The explanted lumbar spine was palpated gently, and lateral side-bending motion at the L4-L5 level was compared with the motion at the adjacent levels above (L3-L4) and below (L5-L6). The absence of motion was considered as successful fusion. Any motion detected between the transverse processes was considered a failure of fusion. The spine was designated as "not fused" if any of the three observers graded it as not fused. The spines were scored as either fused or not fused on both the right and left sides. The fusion rate then was calculated.
Radiographic Analysis
The explanted spines obtained at 6 or 12 weeks after surgery were photographed using an X-ray apparatus (power, 30 kV and 15 mA; crystal-focal point distance, 45 cm; acquisition time, 20 s; Softex CSM-2; Softex, Tokyo, Japan) employing HS Fuji Softex film (Fuji Film, Tokyo, Japan). In each rat, fusion between the L4 and L5 transverse processes was recorded as a percentage of the total area between L4 and L5 that was filled with new bone. Three independent observers blinded to the study design scored the extent of bone formation in each rat, using a 3-point scale: 0, no bone formation; 1, bone filling less than 50% of the area; 2, bone filling 50-100% of the area. The spines were scored on both the right and left sides.
Micro-CT Analysis
Next, the spines were scanned using a micro-CT device (SkyScan 1172; Bruker-microCT, Kontich, Belgium) with a voxel size of 20 mm. The data were collected at 100 kV and 100 mA, and reconstructed using the cone-beam algorithm. Each spine was set on the object stage, and sample scanning was performed over a rotation of 180˚, with an exposure time of 105 ms. A cylindrical volume of interest with a diameter of 20 mm and a height of 27 mm was selected, which displayed the microstructure of the rat vertebrae comprising cortical and cancellous bone. Data analysis was performed using specialized software (SkyScan CT-Analyzer; BrukermicroCT), and the analysis involved the area from the top of the L4 transverse processes to the bottom of the L5 transverse processes, including the vertebrae. The spines were analyzed on both the right and left sides. In the threedimensional analysis, tissue volume, bone volume, trabecular thickness, trabecular spacing, and bone volume fraction were measured.
Histological Analysis
The explanted spines were fixed in 40% ethanol, decalcified using standard 10% decalcifying solution HCl (Cal-Ex; Fischer Scientific, Fairlawn, NJ), washed with running tap water, and then transferred to 75% ethanol. Serial sagittal sections near the transverse processes were carefully cut at the level of the left and right transverse processes. The specimens were embedded in paraffin wax for sectioning. Sagittal sections (5 mm) were cut from the paraffin blocks using a microtome (LS-113; Yamato Kohki Industrial Co., Ltd., Saitama, Japan). The sections were stained with hematoxylin and eosin for evaluation of basic morphology. Three independent observers blinded to the study design scored bone formation on the histologic samples. Histologic fusion was defined as the presence of bony trabeculae bridging from one transverse process to the next. Fusion masses were assessed, and the extent of new bone formation was scored using the following scoring criteria: 0, fibrocartilage tissue filling less than 25% of the gap area; 1, fibrocartilage tissue filling less than 25-75% of the gap area; 2, fibrocartilage and bone tissue filling 75-99% of the gap area; and 3, fully bridged, with mature bone tissue. The spines were scored on both the right and left sides.
Statistical Methods
A dedicated program (SPSS version 13; IBM Corporation, Armonk, NY) was used for all statistical analyses, which included analysis of variance with a significance threshold set at 0.05. A kappa statistic was calculated as a measure of interobserver reliability of the three independent observers blinded to the study design. The kappa statistic corrects the observed agreement for possible chance agreement among observers. Agreement was rated as follows: Poor, 
RESULTS
No pre-or postoperative abnormal behavior or neurologic deficit was noted in the 36 rats included in the study. The rats were humanly euthanized at 6 (group I: n ¼ 7, group II: n ¼ 9) or 12 weeks (group I: n ¼ 10, group II: n ¼ 10) after surgery and explanted the spines. Table 1 shows the proportion of subjects in each group judged as "fused" by the three independent evaluators; consistent agreement was noted among the evaluators (k ¼ 0.822). At 6 weeks, 3 segments (the spines were analyzed on both the right and left sides) in group II (n ¼ 9, segments ¼ 18) were assessed as fused (fusion rate, 16.7%), while 0 segments in group I (n ¼ 7, segments ¼ 14) exhibited fusion (fusion rate, 0%). At 12 weeks, 6 segments in group II (n ¼ 10, segments ¼ 20) were assessed as fused (fusion SIMVASTATIN AND SPINAL FUSION rate, 30.0%), while 0 segments in group I (n ¼ 10, segments ¼ 20) exhibited fusion (fusion rate, 0%). The 0.5 mg simvastatin groups had higher fusion rates than the PBS groups. Significantly higher fusion rates were observed in group II than in groups I at both 6 or 12 weeks after surgery (p < 0.05).
Manual Assessment of Fusion
Radiographic Findings
Radiographs were obtained for the spines explanted at 6 or 12 weeks postoperatively. Consistent agreement (k ¼ 0.816) was noted among the three independent observers who graded the radiographs on both the right and left sides. The average radiographic evaluation scores for each group are shown in Table 2 , and representative anteroposterior radiographs for each group are shown in Figure 1 . Bony bridging was difficult to detect in group I, for rats euthanized at either 6 (Fig. 1A ) or 12 weeks (Fig. 1C) after surgery. Alternatively, spines from group II showed evidence of bone formation between the L4 and L5 transverse processes, and bony bridging was more pronounced in rats euthanized at 12 weeks postoperatively (Fig. 1D ) than in those euthanized at 6 weeks postoperatively (Fig. 1B) . The radiographic scores at both 6 and 12 weeks postoperatively were significantly higher in group II than in group I.
Micro-CT Findings
Representative three-dimensional anteroposterior images for each group are shown in Figure 2 . At 6 weeks, the gaps between the transverse processes were clearly observed in group I ( Fig. 2A) , while both the gap and mineralized callus bridging could be detected)in groups II (Fig. 2B) . At 12 weeks, the gaps between the transverse processes were still clearly observed in group I ( Figure 2C ), whereas the gaps were nearly invisible in group II (Fig. 2D) , although the mineralized callus bridging was deemed insufficient. Computer analysis of the micro-CT images revealed that tissue volume at 6 weeks and bone volume of the callus at both 6 and 12 weeks were higher in group II than in group I, although the differences did not reach statistical significance (Tables 3 and 4) . Group II animals, euthanized at 12 weeks postoperatively. The gaps between the transverse processes were clearly observed in group I, at both 6 and 12 weeks postoperatively. In contrast, mineralized callus bridging was detected in group II at both time points, with more pronounced bridging at 12 weeks postoperatively, when the gaps were nearly invisible.
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Histological Findings
Representative histologic image of the spines are shown in Figure 3 . At 6 weeks, group I showed formation of thick individual trabeculae in the transverse processes, but with fibrotic tissue and muscle fiber between the transverse processes ( Fig. 3A and  B) , whereas group II showed distribution of cartilaginous tissue and no woven bone between the transverse processes ( Fig. 3C and D) . At 12 weeks, group I demonstrated occasional evidence of new bone formation, either originating from the decorticated transverse process or from normal remodeling, but this new bone formation did not bridge the gap between the two transverse processes and was not considered as fusion ( Fig. 3E and F) . In contrast, group II demonstrated new bone formation between the transverse processes, with mature osteoid tissue, trabecular structures, and bone marrow cavities ( Fig. 3G and H) . At 12 weeks postoperatively, histologic fusion scores were significantly higher in group II than in group I (Table 5) .
DISCUSSION
In the present study, we investigated the effect of locally applied simvastatin in a rat model of spinal fusion. Our results represent the first evidence indicating that locally applied simvastatin was efficacious in promoting the fusion process in a rat model. It is generally considered that the skeletal anabolic effect of statins mainly consists of increasing the expression of BMP-2, which is an autocrine-paracrine factor for osteoblast differentiation. Statins have been shown to stimulate BMP-2 transcription and increased endogenous BMP-2 mRNA and protein expression in human osteoblastic cells. 12 The antiresorptive effect of statins on osteoclast numbers is thought to result from the enhanced production of osteoprotegerin in osteoblasts. 15 Several studies have been conducted to investigate the effects of systemically administered statins on bone healing, and positive results have been reported. [16] [17] [18] [19] However, because of their enhanced liver-target property, statins do not accumulate in the bone, and their effects after systemic administration appear to be minimal, as less than 5% of the oral dose reaches systemic circulation. 11 High doses of statins can cause liver failure, kidney disease, and rhabdomyolysis. 20 Therefore, local application of statins is preferable, in order to prevent systemic side effects. However, only few studies investigated the effect of local application of statins in terms of bone formation. [21] [22] [23] [24] Wang et al. found that simvastatin stimulates BMP-2 transcription and increase endogenous BMP-2 mRNA and protein expression in human osteoblastic cells, and concluded that local application of simvastatin could promote fracture healing in ovariectomized rats. 22 Pauly et al. used a rat model of tibia fracture and found that simvastatin-coated osteosynthetic implants provided significantly improved bone formation and increased torsional stiffness compared to uncoated implants, and the effect was similar to that provided by BMP-2-coated implants. 25 Lee et al. used a rat model of mandibular defect, and showed that, compared to rats in the control group, bone formation rate was significantly higher in a group of rats that had received gels infused with 0.5 mg simvastatin gel. 26 Ezilganli et al. used a rat model of diabetes with critical bone defects, and reported that both the volume and area of regenerated bone were higher in rats that had received local simvastatin application than in rats in the control group, but the differences were not statistically significant. 27 In the present study, we investigated the effect of locally applied simvastatin in a rat model of spinal fusion and found that local simvastatin application increased bone formation between the transverse processes. The radiographic and histologic fusion scores of the simvastatin group were significantly higher than those of the control group at both 6 and 12 weeks after surgery. Micro-CT analysis revealed the tissue and bone volumes of the callus were higher than those in the control group, but the difference was not significant. Histologic analysis of the spines in simvastatin groups demonstrated new bone formation between the transverse processes and showed mature osteoid tissue, trabecular structures, and bone marrow cavities after 12 weeks. In contrast, control group showed the formation of individual trabeculae in the transverse processes, which were much thicker in size and much less narrow but there was fibrosis tissue and muscle fiber between the transverse processes after 12 weeks.
On the basis of histometric analysis, Thylin et al. and Stein et al. found inflammation, edema, and crust formation when high doses of simvastatin were used. However, they also found increased bone formation. 28, 29 Cyclooxygenase inflammation appears to be necessary for in vivo bone growth. 29, 30 Stein et al. found that lower doses of simvastatin, such as 0.5 mg, reduced inflammation levels without harming bone anabolic effects. 29 In fact, when we used a 0.5-mg dose of simvastatin, inflammation and crust formations were not significant, whereas mature osteoid tissue, trabecular structures, and bone marrow cavities were formed after 12 weeks.
Because clinical use of BMP-2 is associated with high costs, statins provide an inexpensive, widely approved, and well-tolerated alternative therapeutical option, with a convenient side-effect profile. 31 However, no member of the statin family seems suitable to target bone regeneration. Though statins share the same metabolic target, they differ in their biochemical properties and, therefore, in their effect on bone tissue. Hydrophilic agents (such as pravastatin) barely penetrate bone cell membranes and show no effect on BMP-2 expression, 13 while lipophilic statins (such as simvastatin) cross cellular membranes nonselectively by passive diffusion. 32 Since statins primarily target liver metabolism and are poorly biodistributed, 11 local application is preferred, as it reduces systemic metabolism. Local application of drugs from bioactive carrier polymers may help to increase the drug availability at the site of bone fusion and to lower the required drug doses, minimizing systemic side effects. The present study showed that simvastatin applied at the surgical site is efficient in increasing callus volume in spinal fusion. However, in the present study, we evaluated the results at 12 weeks postoperatively, and did not investigate any long-term effects. Furthermore, it is well known that control and stimulation of bone growth in larger animals is more difficult, and that high bone-forming ability is required for adequate spinal fusion in humans. In addition, the long-term effects of simvastatin remain unknown. In the present study, we have decided the doses for simvastatin at the surgical site in reference to the previous paper. The appropriate dosage, precise fusion rate, and fusion mechanisms were not investigated in the current study. To validate the efficacy and safety of locally administered simvastatin, further studies involving large animals and human subjects are required before the approach can be recommended for clinical use.
In conclusion, the present study showed the effect of bone formation with locally applied simvastatin was efficacious in our rat model of spinal fusion. Compared to other bone-targeting factors such as BMP-2, the effect of it with locally applied simvastatin was not so strong from our results. However, simvastatin is inexpensive and well-tested, with a beneficial sideeffect profile and it may have the potential effect by optionally combining other agents. Additionally, the efficacy and safety of simvastatin in large animals and humans remain unclear, and further studies are warranted in this direction. Despite these issues, our results suggest that simvastatin facilitates spinal fusion and has potential clinical application.
